In two eight-week studies, the proportions of patients on the combination product who achieved Investigator Global Assessment success (clear or almost clear with at least a two-grade improvement over baseline) were approximately 45% and 35%, versus 12% or less for vehicle (P<0.001).
The trend toward combination products in psoriasis will continue to grow, says Dr. Pariser.
“We’re seeing more of these combination products being tested and marketed. It’s taking advantage of the long-standing practice of dermatologists to do compounding. It’s a natural extension of dermatology that we’ve been doing for a long time.”
Dr. Pariser is a current or previous investigator and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Merck, Novartis, Ortho Dermatologics, Pfizer, Promius and Sun Pharma.
David M Pariser MD. “Combination Therapy in Managing Psoriasis Patients.” South Beach Symposium. February 8, 2020.